Extreme Movers: Gemini 3 Pro's picks for 2026-10-20
Gemini 3 Pro picked IRON, CLF, ARQT, DJT, FMC for a 1-day horizon. Average directional return: -0.37%. Directions called correctly: 40%.
| Experiment | Extreme Movers |
|---|---|
| Model | Gemini 3 Pro |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-20 |
| Measured to | 2026-10-21 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -0.37% |
| Directions called correctly | 40% |
| Benchmark return | +0.13% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | IRON | up | +1.69% | +1.69% | 78% | +1.56% | Yes |
| 2 | CLF | up | +4.80% | +4.80% | 74% | +4.67% | Yes |
| 3 | ARQT | up | -0.80% | -0.80% | 70% | -0.92% | No |
| 4 | DJT | down | +2.75% | -2.75% | 68% | -2.87% | No |
| 5 | FMC | up | -4.79% | -4.79% | 62% | -4.92% | No |
The model's market view
US equities reflect ongoing sector dispersion where stock-specific catalysts, particularly biotech Phase 3 readouts and materials Q3 earnings reports, drive outsized single-day performance compared to broad index moves.
Why each pick
IRON
Disc Medicine surged 38.9% following positive Phase 3 clinical trial results for its rare blood disorder therapeutic, prompting price target raises across multiple Wall Street firms. Strong buying volume and a strengthened balance sheet via pre-funded warrants support a continuation hypothesis. Key risks include clinical development delays and secondary equity dilution.
CLF
Cleveland-Cliffs reported Q3 2026 adjusted EBITDA of $612M, significantly exceeding expectations and guidance, while raising its Q4 EBITDA outlook to $715M and forecasting 2027 EBITDA above $4B. Upgrades from major brokerages and hot-rolled coil steel pricing resilience favor positive momentum continuation. Primary risks stem from macro automotive demand slowdowns and steel price volatility.
ARQT
Arcutis Biotherapeutics gained 10.7% after Wall Street initiated coverage with an Overweight rating, highlighting commercial acceleration for its flagship dermatology treatment Zoryve. High volume and steady revenue expansion underpin a continuation thesis. Key downside risks include valuation multiple compression and commercial competition in topical dermatology.
DJT
Trump Media & Technology Group fell 8.0% to multi-month lows as ongoing operating losses ($712M TTM net loss on $3.7M revenue) and technical breakdowns below key moving averages continue to weigh heavily on valuation. Continuation hypothesis points to sustained selling pressure. Primary upside risks include news-driven momentum spikes or unexpected retail short squeezes.
FMC
FMC Corporation dropped 35.6% over recent sessions into heavily oversold territory (RSI ~30) due to crop chemical destocking headwinds. Trading at 0.40x sales and 0.64x book value, a mean-reversion reversal hypothesis is selected ahead of its upcoming Q3 earnings call. Major risks include persistent elevated leverage ($4.4B debt) and extended inventory adjustment cycles in international markets.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| GPT-6 | ALM, CLF, IBRX, IRON, MANE | -0.51% | 40% |
| Muse Spark 1.1 | HAS, GM, GE, IREN, KVYO | +2.01% | 60% |
| Perplexity | WDC, DDOG, CLF, AGIO, AMP | +0.14% | 40% |
| Grok 4.5 | CLF, IRON, WDC, AMZN, MOS | +2.30% | 80% |
| DeepSeek | CLF, WDC, CTRA, AMP, DDOG | -1.17% | 25% |
| Claude Sonnet 5.5 | ALM, MANE, CLF, IRON, AGIO | +0.82% | 60% |
Written up on ForecastNest Insights: Extreme Movers: Gemini 3 Pro's picks for 2026-10-20.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.